BSAM
AGIO icon

Blue Sky Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Blue Sky Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6,210
Closed -$320K – 84
2017
Q2 		$320K Buy
6,210
+3,998
+181% +$204K 0.17% 64
2017
Q1 		$129K Buy
+2,212
New +$106K 0.08% 70

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Blue Sky Asset Management's AGIO Position: Q3 2017 in Review

Blue Sky Asset Management sold out of Agios Pharmaceuticals (AGIO) in Q3 2017, closing a stake of 6,210 shares — an estimated $320K sold.

Blue Sky Asset Management first reported a position in AGIO in Q1 2017 and held it in 2 quarters. The position peaked at $320K in Q2 2017. 171 funds tracked by Wall St. Rank hold AGIO as of Q3 2017.

  • Blue Sky Asset Management reported no remaining Agios Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Blue Sky Asset Management sold 6,210 Agios Pharmaceuticals shares in Q3 2017, an estimated $320K.
  • Blue Sky Asset Management first reported a position in Agios Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Blue Sky Asset Management's Agios Pharmaceuticals position peaked at $320K in Q2 2017.
  • 171 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2017.

Based on Blue Sky Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.